Abstract Number: 619 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). We examined tofacitinib efficacy in patients (pts) with active…Abstract Number: 2280 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Switching to Adalimumab As the Second- and Third-Line Biological Drug in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: The range of biological drugs currently used in JIA therapy includes not only anti-TNF but also other varieties. However, despite the high effectiveness and…Abstract Number: 961 • 2017 ACR/ARHP Annual Meeting
Adalimumab Reduces CXCR4 Expression during Inflammatory Arthritis and in Fibroblast-like Synoviocytes and Osteoclasts Under Chronic TNF Exposure
Background/Purpose: The CXCL12/CXCR4 chemokine axis has been implicated in the pathogenesis of RA. The expression of this chemokine and receptor has been shown to be…Abstract Number: 2283 • 2017 ACR/ARHP Annual Meeting
Adalimumab Therapy in Juvenile Idiopathic Arthritis: Addition of Lidocaine for Prevention of Injection Site Pain or Not? That Is the Question. a Comparison Study
Background/Purpose: Up to 37% of patients prescribed adalimumab (AD) report significant injection-site pain (Registered Prescribing Information, 2016). For AD to be a stable pre-filled product,…Abstract Number: 1038 • 2017 ACR/ARHP Annual Meeting
Impact of Patient Support Program Utilization on Patient Activation Measure Scores Among Patients with Rheumatoid Arthritis
Background/Purpose : AbbVie’s Patient (pt) Support Program (PSP) is offered to pts who are prescribed adalimumab (ADA) for their Rheumatoid arthritis (RA). The purpose of…Abstract Number: 2298 • 2017 ACR/ARHP Annual Meeting
Etanercept, Adalimumab and Methotexate Utilization By Juvenile Idopathic Arthritis Patients and the Occurrence of Uveitis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic arthritis with onset before 16 years of age, that persists for at least 6 weeks, and has…Abstract Number: 1155 • 2017 ACR/ARHP Annual Meeting
Impact of Adalimumab on Immunosuppressant Use in Patients with Active and Inactive Non-Infectious Intermediate, Posterior, or Pan-Uveitis in the Ongoing Open Label Study: Visual-III
Background/Purpose: The morbidity associated with the use of immunosuppressants is well described in patients (pts) with autoimmune ophthalmic disease and presents a challenge to treating…Abstract Number: 2393 • 2017 ACR/ARHP Annual Meeting
Evaluation of Live Zoster Vaccine in a Subset of Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, and Adalimumab with Methotrexate: Results from a Phase 3b/4 Randomized Trial
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA are at increased risk for herpes…Abstract Number: 1352 • 2017 ACR/ARHP Annual Meeting
The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis
Background/Purpose: Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) with rheumatoid arthritis (RA) patients (pts), resulting in the…Abstract Number: 2440 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy, Safety and Immunogenicity Results from a Randomized, Double-Blind, Phase III Confirmatory Efficacy and Safety Study Comparing GP2017, a Proposed Biosimilar, with Reference Adalimumab
Background/Purpose: Based on the evaluation of physicochemical, biological, preclinical, and clinical data, a biosimilar may be approved for use in the same indications for which…Abstract Number: 1418 • 2017 ACR/ARHP Annual Meeting
The Value of Adalimumab Trough Levels and Clinical Assessments in Predicting Clinical Response in Patients with Established Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Background/Purpose: Low trough levels of the tumor necrosis factor inhibitor, adalimumab (ADL), and anti-ADL antibodies (AAA) were reported to be correlated with lack of response…Abstract Number: 2442 • 2017 ACR/ARHP Annual Meeting
Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study
Background/Purpose: Clinical equivalence has been shown for BI 695501 and the adalimumab reference product (RP) through similar ACR20 response at Weeks (wks) 12 and 24…Abstract Number: 1419 • 2017 ACR/ARHP Annual Meeting
Characteristics of Patients with Early Rheumatoid Arthritis Who Have a Delayed Response to Treatment with Methotrexate in Monotherapy or in Combination with Adalimumab
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), treat-to-target recommendations call for adjustment of treatment if a target is not met within 3-6 months (mths)…Abstract Number: 2443 • 2017 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Single-Dose, Three-Arm Parallel Trial to Determine the Pharmacokinetics and Safety of GP2017, EU- and US-Adalimumab in Healthy Male Subjects
Background/Purpose: GP2017 is a proposed adalimumab biosimilar that has been shown to be similar to reference adalimumab at an analytical and preclinical level. The aim…Abstract Number: 1420 • 2017 ACR/ARHP Annual Meeting
The Ability of Patients with Early Rheumatoid Arthritis to Taper Low-Dose Glucocorticoids on Methotrexate Monotherapy and in Combination with Adalimumab
Background/Purpose: Low dose glucocorticoids (GCs) are recommended in combination with ≥1 synthetic DMARDs as part of the initial treatment strategy in rheumatoid arthritis (RA), with…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 17
- Next Page »